SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 30, 2002; DOI 10.1182/blood-2001-12-0304. This Article Full Text (PDF) All Versions of this Article: 2001-12-0304v1 100/3/761    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Schmitz, N. Articles by Gratwohl, A. Search for Related Content PubMed PubMed Citation Articles by Schmitz, N. Articles by Gratwohl, A. Social Bookmarking                   What's this? Submitted December 21, 2001 Accepted March 13, 2002 Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia Norbert Schmitz*, Meral Beksac, Dirk Hasenclever, Andrea Bacigalupo, Tapani Ruutu, Arnon Nagler, Eliane Gluckman, Nigel Russell, Jane F Apperley, Norbert C Gorin, Jeff Szer, Ken Bradstock, Agnes Buzyn, Peter Clark, Keith Borkett, and Alois Gratwohl * Corresponding author; email: Norbert.Schmitz{at}ak-stgeorg.lbk-hh.de. Allogeneic mobilized peripheral blood progenitor cells instead of bone marrow are increasingly used to restore hematopoiesis after myeloablative therapy.Data supporting this important change of clinical practice are scarce. We therefore, assigned patients with early leukemias to peripheral blood or bone marrow transplantation; the occurrence of acute and chronic graft-versus-host disease, survival, trans-plant-related mortality, and relapse rates were compared. Three hundred and fifty patients between 18 and 55 years of age with acute leukemias in re-mission or chronic myelogenous leukemia in first chronic phase were randomized to receive either fil-grastim-mobilized peripheral blood progenitor cells or bone marrow cells from HLA-identical sibling do-nors after standard high-dose chemoradiotherapy. Neutrophil and platelet recovery occurred significantly faster after transplantation of peripheral blood progenitor cells than after bone marrow transplantation. Acute graft-versus-host disease of grades II-IV was significantly more frequent in recipients of peripheral blood progenitor cells than in recipients of marrow cells (52% versus 39%, odds ratio 1.74, 95% confidence interval 1.12 to 2.69, P = 0.013). The cumulative incidence of chronic graft-versus-host disease was 67% with peripheral blood progenitor cell transplants and 54% with bone marrow cells (hazard ratio 1.67, 95% confidence interval 1.15 to 2.42, P = 0.0066). The estimated overall probability of survival at two years was 65% with either source of stem cells (hazard ratio 1.15, 95% confidence interval 0.79 to 1.67, P = 0.46). Disease-free survival, transplant-related mortality at day 100, and relapse rates did not significantly differ between treatment arms. Peripheral blood is an equivalent source of hematopoietic stem cells compared to bone marrow if administered to patients with standard-risk leukemias. Long-term observation of patients with different diseases and stages of disease is necessary to ultimately define the role of both sources of stem cells. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Gallardo, R. de la Camara, J. B. Nieto, I. Espigado, A. Iriondo, A. Jimenez-Velasco, C. Vallejo, C. Martin, D. Caballero, S. Brunet, et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study Haematologica, September 1, 2009; 94(9): 1282 - 1288. [Abstract] [Full Text] [PDF] G. G. Laport, J. C. Alvarnas, J. M. Palmer, D. S. Snyder, M. L. Slovak, A. M. Cherry, R. M. Wong, R. S. Negrin, K. G. Blume, and S. J. Forman Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen Blood, August 1, 2008; 112(3): 903 - 909. [Abstract] [Full Text] [PDF] A. A. Jakubowski, T. N. Small, J. W. Young, N. A. Kernan, H. Castro-Malaspina, K. C. Hsu, M.-A. Perales, N. Collins, C. Cisek, M. Chiu, et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin Blood, December 15, 2007; 110(13): 4552 - 4559. [Abstract] [Full Text] [PDF] H. Schrezenmeier, J. R. Passweg, J. C. W. Marsh, A. Bacigalupo, C. N. Bredeson, E. Bullorsky, B. M. Camitta, R. E. Champlin, R. P. Gale, M. Fuhrer, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia Blood, August 15, 2007; 110(4): 1397 - 1400. [Abstract] [Full Text] [PDF] A. Locasciulli, R. Oneto, A. Bacigalupo, G. Socie, E. Korthof, A. Bekassy, H. Schrezenmeier, J. Passweg, M. Fuhrer, and on the behalf of the Severe Aplastic Anemia Workin Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation Haematologica, January 1, 2007; 92(1): 11 - 18. [Abstract] [Full Text] [PDF] I. Yakoub-Agha, F. Mesnil, M. Kuentz, J. M. Boiron, N. Ifrah, N. Milpied, S. Chehata, H. Esperou, J.-P. Vernant, M. Michallet, et al. Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen-Identical Siblings Versus Human Leukocyte Antigen-Allelic-Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy J. Clin. Oncol., December 20, 2006; 24(36): 5695 - 5702. [Abstract] [Full Text] [PDF] N. Schmitz, M. Eapen, M. M. Horowitz, M.-J. Zhang, J. P. Klein, J. D. Rizzo, F. R. Loberiza, A. Gratwohl, and R. E. Champlin Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation Blood, December 15, 2006; 108(13): 4288 - 4290. [Abstract] [Full Text] [PDF] Stem Cell Trialists' Collaborative Group Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials J. Clin. Oncol., August 1, 2005; 23(22): 5074 - 5087. [Abstract] [Full Text] [PDF] R. E. Curtis, C. Metayer, J. D. Rizzo, G. Socie, K. A. Sobocinski, M. E. D. Flowers, W. D. Travis, L. B. Travis, M. M. Horowitz, and H. J. Deeg Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study Blood, May 15, 2005; 105(10): 3802 - 3811. [Abstract] [Full Text] [PDF] M. Remberger, D. W. Beelen, A. Fauser, N. Basara, O. Basu, and O. Ringden Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors Blood, January 15, 2005; 105(2): 548 - 551. [Abstract] [Full Text] [PDF] D. A. Wall Allogeneic Peripheral Blood Versus Bone Marrow Transplantation: Children Are Small Adults and More J. Clin. Oncol., December 15, 2004; 22(24): 4865 - 4866. [Full Text] [PDF] M. Eapen, M. M. Horowitz, J. P. Klein, R. E. Champlin, F. R. Loberiza Jr, O. Ringden, and J. E. Wagner Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry J. Clin. Oncol., December 15, 2004; 22(24): 4872 - 4880. [Abstract] [Full Text] [PDF] R.M. Nagler and A. Nagler The Molecular Basis of Salivary Gland Involvement in Graft-vs.-Host Disease Journal of Dental Research, February 1, 2004; 83(2): 98 - 103. [Abstract] [Full Text] [PDF] R. M. Stone, M. R. O'Donnell, and M. A. Sekeres Acute Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 98 - 117. [Abstract] [Full Text] [PDF] N. C. Gorin, M. Labopin, V. Rocha, W. Arcese, M. Beksac, E. Gluckman, O. Ringden, T. Ruutu, J. Reiffers, G. Bandini, et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow Blood, October 15, 2003; 102(8): 3043 - 3051. [Abstract] [Full Text] [PDF] Y. Kanda, S. Chiba, H. Hirai, H. Sakamaki, T. Iseki, Y. Kodera, T. Karasuno, S. Okamoto, N. Hirabayashi, K. Iwato, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000) Blood, August 15, 2003; 102(4): 1541 - 1547. [Abstract] [Full Text] [PDF] J. A. Perez-Simon, M. Diez-Campelo, R. Martino, A. Sureda, D. Caballero, C. Canizo, S. Brunet, A. Altes, L. Vazquez, J. Sierra, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation Blood, August 1, 2003; 102(3): 1108 - 1113. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020